DIABETES SPOTLIGHT: Annual Trend Report Looks at New Diabetes Trends
Investigating Top Diabetes Trends by Lines of Business
BY: KAREN WATKINS & SUSAN TRIEU
Diabetes spending will continue to increase as new pipeline agents like oral semaglutide enter the market. For now, insulin still dominates the diabetes therapeutic class, accounting for 49% of market share. Newer generation, non-insulin products, like DPP4, SGLT2 or GLP-1s, or combinations that contain them, now make up a combined 50% of market share.
GLP-1 agonists and SGLT2 inhibitors have recently gained more market share than DPP-IV inhibitors due to their greater ability to reduce glucose levels and achieve positive morbidity and mortality study results.
Over the past five years, the rapidly growing GLP-1 market has experienced a remarkable 76% cost increase. GLP-1 list prices are increasing at a higher rate than insulin, which has increased by 54% since 2014.5
Top Diabetes 2018 Trends by Line of Business
Download the 2018 Annual Trend Report